Champions Oncology Says New Xenograft Models Will Aid Prostate Cancer Research

Champions Oncology Says New Xenograft Models Will Aid Prostate Cancer Research
Champions Oncology has added new cohorts of patient-derived xenograft (PDX) models to its TumorBank, expanding the company’s product line in castrate-resistant prostate cancer (CRPC) and other ailments. The new PDX models will support drug development in oncology programs and in translational industry and academic research. CRPC is a type of prostate cancer that no longer responds to

Knowledge is power when living with prostate cancer.

Get access to the web’s leading Prostate Cancer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *